An interim analysis was pre-planned after 500 patients achieved 1 year of follow-up. This trial is registered withClinicalTrials.gov, numberNCT01367665 . The study is still ongoing.
Book Title: Vismodegib in Patients with Advanced Basal Cell Carcinoma (STEVIE): a Pre-planned Interim Analysis of an International, Open-label Trial
Author:
Published on 2015 by
ISBN: /
Total Page:
Book Category:
Book is About: Carcinoma
Download Vismodegib in Patients with Advanced Basal Cell Carcinoma (STEVIE): a Pre-planned Interim Analysis of an International, Open-label Trial eBook
Background: The Hedgehog pathway inhibitor vismodegib has shown clinical benefit in patients with advanced basal cell carcinoma and is approved for treatment of patients with advanced basal cell carcinoma for whom surgery is inappropriate. STEVIE was designed to assess the safety of vismodegib in a situation similar to routine practice, with a long follow-up. Methods: In this multicentre, open-label trial, adult patients with histologically confirmed locally advanced basal cell carcinoma or metastatic basal cell carcinoma were recruited from regional referral centres or specialist clinics. Eligible patients were aged 18 years or older with an Eastern Cooperative Oncology Group (ECOG) performance status of 0–2, and adequate organ function. Patients with locally advanced basal cell carcinoma had to have been deemed ineligible for surgery. All patients received 150 mg oral vismodegib capsules once a day on a continuous basis in 28-day cycles. The primary objective was safety (incidence of adverse events until disease progression or unacceptable toxic effects), with assessments on day 1 of each treatment cycle (28 days) by principal investigator and coinvestigators at the site. Efficacy variables were assessed as secondary endpoints. The safety evaluable population included all patients who received at least one dose of study drug. Patients with histologically confirmed basal cell carcinoma who received at least one dose of study drug were included in the efficacy analysis. An interim analysis was pre-planned after 500 patients achieved 1 year of follow-up. This trial is registered withClinicalTrials.gov, numberNCT01367665 . The study is still ongoing. Findings: Between June 30, 2011, and Nov 6, 2014, we enrolled 1227 patients. At clinical cutoff (Nov 6, 2013), 499 patients (468 with locally advanced basal cell carcinoma and 31 with metastatic basal cell carcinoma) had received study drug and had the potential to be followed up for 12 months or longer. Treatment was discontinued in 400 (80%) patients; 180 (36%) had adverse events, 70 (14%) had progressive disease, and 51 (10%) requested to stop treatment. Median duration of vismodegib exposure was 36·4 weeks (IQR 17·7–62·0). Adverse events happened in 491 (98%) patients; the most common were muscle spasms (317 [64%]), alopecia (307 [62%]), dysgeusia (269 [54%]), weight loss (162 [33%]), asthenia (141 [28%]), decreased appetite (126 [25%]), ageusia (112 [22%]), diarrhoea (83 [17%]), nausea (80 [16%]), and fatigue (80 [16%]). Most adverse events were grade 1 or 2. We recorded serious adverse events in 108 (22%) of 499 patients. Of the 31 patients who died, 21 were the result of adverse events. As assessed by investigators, 302 (66·7%, 62·1–71·0) of 453 patients with locally advanced basal cell carcinoma had an overall response (153 complete responses and 149 partial responses); 11 (37·9%; 20·7–57·7) of 29 patients with metastatic basal cell carcinoma had an overall response (two complete responses, nine partial responses). Interpretation: This study assessed the use of vismodegib in a setting representative of routine clinical practice for patients with advanced basal cell carcinoma. Our results show that treatment with vismodegib adds a novel therapeutic modality from which patients with advanced basal cell carcinoma can benefit substantially. Funding: F Hoffmann-La Roche.
Our website offers free Carcinoma Ebooks to download. Vismodegib in Patients with Advanced Basal Cell Carcinoma (STEVIE): a Pre-planned Interim Analysis of an International, Open-label Trial is the one of great book to have from us, a free ebooks portal, the best free ebooks download library. You can find and download free ebooks in categories. No registration is required to download free e-books. We have huge collection of Carcinoma and ebooks. Each downloadable ebook has a short review with a description. You can find over thousand of ebooks that are free to download. Get ton of books with us, the open directory for free ebooks and download links, the best place to read ebooks and search free download ebooks.Carcinoma ebooks free
download Vismodegib in Patients with Advanced Basal Cell Carcinoma (STEVIE): a Pre-planned Interim Analysis of an International, Open-label Trial ebook as PDF, EPUB, MOBI, AZW and AZW3, FB2, DJVU, LIT, RFT, IBA, LRS, LRF, and LRX.
download ebooks
There are so many ebooks about Vismodegib in Patients with Advanced Basal Cell Carcinoma (STEVIE): a Pre-planned Interim Analysis of an International, Open-label Trial that are available to have. Thinking of having Vismodegib in Patients with Advanced Basal Cell Carcinoma (STEVIE): a Pre-planned Interim Analysis of an International, Open-label Trial ebook? You are in the right place. Get the ebook Vismodegib in Patients with Advanced Basal Cell Carcinoma (STEVIE): a Pre-planned Interim Analysis of an International, Open-label Trial by: .
Book Details:
- Book was ranked at 8 by Google Books for Vismodegib in Patients with Advanced Basal Cell Carcinoma (STEVIE): a Pre-planned Interim Analysis of an International, Open-label Trial
- Vismodegib in Patients with Advanced Basal Cell Carcinoma (STEVIE): a Pre-planned Interim Analysis of an International, Open-label Trial published by since 2015 with ISBNs. The book ISBN 13 Code is and ISBN 10 Code is
- Reading Mode in Text Status is false and Reading Mode in Image Status is false
- The book has " Pages" is Printed at BOOK under Category
- Rated by Raters and have average rate at ""
- eBook written in en
- Book Preview Address: http://books.google.com/books?id=LUfcvQEACAAJ&dq=Carcinoma&hl=&cd=247&source=gbs_api
Book Preview
The Button is not working? Try The Alternative links for "Vismodegib in Patients with Advanced Basal Cell Carcinoma (STEVIE): a Pre-planned Interim Analysis of an International, Open-label Trial by: ":
- Server 2: SECURE LINK